Use of Biosimilars in Paediatric Inflammatory Bowel Disease: An Updated Position Statement of the Paediatric IBD Porto Group of ESPGHAN

Paediatric IBD Porto group of ESPGHAN

Research output: Contribution to journalArticle

Abstract

Biologic therapies have changed the outcome of both adult and paediatric patients with Inflammatory Bowel Disease (IBD). In September 2013, the first biosimilar of infliximab was introduced into the pharmaceutical market. In 2015, a first position paper on the use of biosimilars in paediatric IBD was published by the ESPGHAN IBD Porto group. Since then, more data have accumulated for both adults and children demonstrating biosimilars are an effective and safe alternative to the originator. In this updated position statement we summarize current evidence and provide joint consensus statements regarding the recommended practice of biosimilar use in children with IBD.

Original languageEnglish
JournalJournal of Pediatric Gastroenterology and Nutrition
DOIs
Publication statusE-pub ahead of print - Aug 30 2018

Fingerprint Dive into the research topics of 'Use of Biosimilars in Paediatric Inflammatory Bowel Disease: An Updated Position Statement of the Paediatric IBD Porto Group of ESPGHAN'. Together they form a unique fingerprint.

  • Cite this